Amt für Wirtschaft und Arbeit, Kanton Basel-Stadt hat dies direkt geteilt
Our tenant, Cellestia Biotech, announces the creation of Anciata Therapeutics in partnership with TVM Capital Life Science. With a joint investment of up to $34 million from TVM and Cellestia Biotech AG and the option to collaborate with ExploR&D, Eli Lilly and Company's early development unit, Anciata is focused on advancing new treatment options in immunology and autoimmunity. This strategic collaboration highlights Cellestia’s ability to translate cutting-edge science into investable, high-impact opportunities. IPX-2017, a novel oral therapeutic targeting autoimmune disorders, showcases the strength of our discovery platform and our focus on addressing areas of high unmet medical need. Full press release: https://lnkd.in/eN_knaAD #TPB #TechParkBasel #Investment #Basel #Biotech Basel Area Business & Innovation Standortförderung, AWA, Kanton Basel-Stadt Amt für Wirtschaft und Arbeit, Kanton Basel-Stadt Raj Lehal, PhD